報告題目：New Advances in Wnt Signaling and Discovery of Bone Therapeutics

報  告 人🦑： Dr. Hua Zhu (David) Ke, Vice President, Head of Bone Therapeutic Area, New Medicines, UCB Pharma, United Kingdom.

報告時間🤵🏻‍♂️：5月16日13:00

報告地點🙇🏿🧑🏽‍🎓：閔行校區生物藥學樓1號樓105會議室

聯  系 人：夏學春 This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

摘要👨🏻‍🔬：Wnt/beta-catenin signaling pathway plays an important role in bone formation and regeneration. Dickkopf-1 (DKK1) and sclerostin are extracellular Wnt antagonists that regulate bone formation by competing with Wnts for binding to the co-receptor lipoprotein-related proteins-5 and -6 (LRP5/6) expressed on the surface of bone cells. This seminar will summarize the up-to-date knowledge regarding the regulation of sclerostin and DKK1 on bone metabolism and fracture repair, and the discovery of new therapeutics for bone diseases such as osteoporosis and fracture healing by antagonizing Wnt inhibitors sclerostin, DKK1 or both.

個人簡介👨🏽‍🦰：The primary research interests of David and his group is to discover and develop novel therapeutics for musculoskeletal diseases with focus on osteoporosis and fracture repair. While in Pfizer (Groton, Connecticut, USA), he and his group performed research on selective estrogen receptor modulator that led to the discovery and development of lasofoxifene. In Amgen (Thousand Oaks, California, USA), he and his group contributed to the development of denosumab, a RANKL antibody, and romosozumab, a sclerostin antibody. In 2010, denosumab was approved for use in postmenopausal osteoporosis under the trade name Prolia, and for the prevention of skeleton-related events in patients with bone metastases from solid tumors under the trade name Xgeva. Romosozumab is an investigational bone-forming agent that is currently in Phase III clinical trials for the treatment of osteoporosis by Amgnen and UCB Pharma. David has authored or co-authored more than 130 peer-reviewed scientific publications, and he is the inventor or co-inventor for 29 patents.